24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
BICALIEVA 50MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | BICALIEVA 50MG |
|---|---|
| Composition | Bicalutamide Tablet IP 50mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Strip (10 x 1 x 10) |
| Country of Origin | India |
Bicalutamide Tablet IP 50mg (Bicalutamide Tablet IP 50mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
BICALIEVA 50MG (Bicalutamide Tablet IP 50mg) is a prescription anti-cancer medicine used in the treatment and management of prostate cancer. It contains Bicalutamide 50mg, a non-steroidal antiandrogen that works by blocking the effects of male hormones (androgens), particularly testosterone, which can stimulate the growth of prostate cancer cells.
Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. Many prostate cancer cells rely on testosterone and other androgens to grow and multiply. BICALIEVA 50MG helps control the disease by preventing these hormones from attaching to cancer cells, thereby slowing cancer growth and reducing tumor progression.
Bicalutamide is widely used as part of hormone therapy for prostate cancer and is often prescribed in combination with other treatments such as luteinizing hormone-releasing hormone (LHRH) agonists or surgical castration. This combined approach helps achieve more effective androgen deprivation, which is an important strategy in prostate cancer management.
BICALIEVA 50MG is commonly prescribed for:
• Advanced Prostate Cancer
• Metastatic Prostate Cancer
• Hormone-Sensitive Prostate Cancer
• Androgen Deprivation Therapy (ADT)
• Combination Prostate Cancer Treatment
• Long-Term Oncology and Urology Care
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and urology treatment.
Patients receiving BICALIEVA 50MG may require regular monitoring of prostate-specific antigen (PSA) levels, liver function, overall treatment response, and routine medical evaluations. These assessments help healthcare providers optimize treatment outcomes and manage potential side effects effectively.
Due to its proven role in hormone-based prostate cancer treatment, BICALIEVA 50MG remains an important medicine in modern oncology and urology care programs.
BICALIEVA 50MG (Bicalutamide Tablet IP 50mg) is primarily used for the treatment and management of prostate cancer.
The medicine is widely used in patients with advanced-stage prostate cancer to help slow disease progression.
Doctors may prescribe Bicalutamide for prostate cancer that has spread beyond the prostate gland.
BICALIEVA is an important part of androgen deprivation therapy (ADT), helping reduce the effect of male hormones on cancer cells.
The medicine is often used alongside LHRH agonists or other hormone-based therapies for enhanced treatment effectiveness.
Bicalutamide supports ongoing prostate cancer control and long-term treatment strategies.
The medicine is frequently included in specialized cancer treatment protocols supervised by oncologists and urologists.
Bicalutamide belongs to a class of medicines known as non-steroidal antiandrogens.
BICALIEVA works by:
• Blocking androgen receptors
• Preventing testosterone from stimulating cancer cells
• Slowing prostate cancer growth
• Reducing tumor progression
• Supporting hormone therapy effectiveness
• Helping manage advanced prostate cancer
This targeted hormonal approach helps control cancer development and improve treatment outcomes.
Like all prescription medicines, BICALIEVA 50MG may cause side effects in some patients. The severity and occurrence of side effects vary depending on individual health conditions and treatment duration.
Many patients experience episodes of warmth, sweating, or flushing.
Hormonal changes may cause breast discomfort or enlargement in some patients.
Weakness, tiredness, and reduced energy levels may occur during treatment.
Reduced libido may develop due to hormone suppression.
Some patients may experience difficulty achieving or maintaining an erection.
Mild nausea or stomach discomfort may occur.
Weight gain or minor body composition changes may be observed.
Certain patients may experience dizziness or lightheadedness.
Digestive disturbances or mild stomach pain may occasionally occur.
Seek immediate medical attention if you experience:
• Severe allergic reactions
• Difficulty breathing
• Chest pain
• Severe liver-related symptoms
• Yellowing of the skin or eyes
• Severe abdominal pain
• Unusual swelling
• Signs of serious infection
Patients should immediately contact their healthcare provider if severe symptoms develop.
The dosage of BICALIEVA 50MG (Bicalutamide Tablet IP 50mg) should always be determined by a qualified healthcare professional.
The severity and progression of the disease influence treatment planning.
Dosage may depend on whether the medicine is being used alongside other hormone therapies.
Age, liver function, and overall health affect treatment decisions.
Doctors may adjust therapy based on clinical response and disease progression.
Previous treatments and coexisting medical conditions may influence dosage recommendations.
• Take the tablet exactly as prescribed.
• Swallow the tablet whole with water.
• Take the medicine at the same time each day.
• Do not skip doses unless advised by your doctor.
• Continue treatment as directed, even if symptoms improve.
• Attend all scheduled medical appointments and monitoring visits.
Regular follow-up helps ensure safe and effective treatment.
Before starting treatment, patients should inform their doctor if they have:
• Liver disease
• Heart disease
• Diabetes
• Hormonal disorders
• Previous cancer treatment complications
• Allergies to medications
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant women should not handle or use this medicine unless specifically instructed by a healthcare professional.
• Store in a cool and dry place.
• Protect from direct sunlight and moisture.
• Keep out of reach of children.
• Store at recommended room temperature.
• Trusted Bicalutamide formulation
• Effective hormone therapy for prostate cancer
• Supports long-term disease management
• Reliable antiandrogen treatment option
• Manufactured under strict pharmaceutical quality standards
• Suitable for modern oncology and urology treatment protocols
• Helps slow prostate cancer progression
It is primarily used for the treatment and management of prostate cancer.
Bicalutamide is a non-steroidal antiandrogen medicine that blocks the action of male hormones involved in prostate cancer growth.
Yes, it is often prescribed alongside LHRH agonists or other hormone therapies.
No, it is a hormone therapy medicine that works differently from chemotherapy.
Yes, by blocking androgen activity, it helps reduce the growth and spread of prostate cancer cells.
Yes, doctors typically recommend PSA monitoring, liver function tests, and routine medical evaluations.
No, treatment should only be modified or discontinued under the supervision of a healthcare professional.
Yes, this medicine should always be used under the guidance of qualified healthcare professionals experienced in oncology and urology care.